Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial

Boehringer Ingelheim GmbH said its experimental hepatitis C oral treatment cleared the virus in as many as 82 percent of patients in a study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.